Immunovant, Inc. (IMVT): Total Assets
$957.01M
As of 2026-03-31
$852.49M
As of 2026-06-30
+33.1%
3-year compound annual growth
+18.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $957.01M | +23.3% | 2026-05-20, Balance as of period end |
| 2025-03-31 | $776.22M | +16.5% | 2026-05-20, Balance as of period end |
| 2024-03-31 | $666.37M | +64.2% | 2025-05-29, Balance as of period end |
| 2023-03-31 | $405.84M | -21.3% | 2024-05-29, Balance as of period end |
| 2022-03-31 | $515.56M | +25.0% | 2023-05-22, Balance as of period end |
| 2021-03-31 | $412.49M | +277.1% | 2022-06-08, Balance as of period end |
| 2020-03-31 | $109.39M | +691.1% | 2021-06-01, Balance as of period end |
| 2019-03-31 | $13.83M | n/a | 2020-06-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 2026-03-31 | $957.01M | +23.3% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $913.17M | +0.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $1.07B | +5.7% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $1.12B | -18.7% |
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $1.14B | -16.7% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.18B | -24.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.33B | +26.3% |
Compare IMVT, VIR, IOVA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗